ライフサイエンスコーパス: hairy cell leukemia

1 time the clinical and pathologic features of hairy cell leukemia.

2 1 in both leukemia and lymphoma, and BRAF in hairy cell leukemia.

3 ll known and revolutionized the treatment of hairy cell leukemia.

4 signaling important for the pathogenesis of hairy cell leukemia.

5 ted kinase (ERK) in the hairy cells (HCs) of hairy cell leukemia.

6 mphomas with villous lymphocytes (SLVLs) and hairy cell leukemia.

7 Only 2 of 40 deaths were attributed to hairy cell leukemia.

8 denosine analog, is clinically effective for hairy cell leukemia.

9 y profile when administered to patients with hairy cell leukemia.

10 BRAF V600E is the genetic lesion underlying hairy-cell leukemia.

11 tive in patients with relapsed or refractory hairy-cell leukemia.

12 ia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma

13 relapse-free survival times in patients with hairy cell leukemia, a disease that historically had bee

14 cally, this paper describes the frequency of hairy cell leukemia among all adult leukemias and charac

15 ons is helpful in the diagnosis of classical hairy cell leukemia and a number of histiocytic neoplasm

16 marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma.

17 Immunotoxin therapy is very effective in hairy cell leukemia and also has activity in other hemol

18 cladribine) is effective in the treatment of hairy cell leukemia and chronic lymphocytic leukemia.

19 lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predo

20 ate of complete remissions in drug-resistant hairy cell leukemia and has a lower response rate in ped

21 RITs have shown efficacy in refractory hairy cell leukemia and in some children with acute lymp

22 with reports of only a few cases of variant hairy cell leukemia and neurological disease associated

23 ladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also

24 e been used to treat many diseases including hairy-cell leukemia and hepatitis B and C and have also

25 CldAdo), which is the drug of choice against hairy-cell leukemia and other neoplasms, from 2'-deoxygu

26 The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature c

27 The description of hairy cell leukemia as a specific clinical entity was pu

28 issions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias w

29 HA22 is very active in drug-resistant hairy cell leukemia but is less active in children with

30 V600E-expressing human primary melanoma and hairy cell leukemia cells.

31 B-Raf kinase (BRAF mutations) are present in hairy-cell leukemia, cutaneous melanoma, thyroid carcino

32 The Hairy Cell Leukemia Foundation convened an international

33 n bone marrow core biopsies of patients with hairy cell leukemia (HCL) after treatment with 2-chlorod

34 s, 28 low grade B-cell lymphomas, 4 cases of hairy cell leukemia (HCL) and 3 plasmacytomas.

35 V600E mutation was reported in all cases of hairy cell leukemia (HCL) but not in other peripheral B-

36 BRAFV600E mutation was recently detected in hairy cell leukemia (HCL) by whole exome sequencing.

37 tic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle

38 Hairy cell leukemia (HCL) derives from a mature B cell a

39 The discovery of effective therapy for hairy cell leukemia (HCL) has increased the relevance of

40 Hairy cell leukemia (HCL) is a chronic B-cell leukemia n

41 Hairy cell leukemia (HCL) is a chronic lymphoproliferati

42 Hairy cell leukemia (HCL) is a chronic mature B-cell neo

43 Hairy cell leukemia (HCL) is a distinct clinicopathologi

44 Hairy cell leukemia (HCL) is a distinct clinicopathologi

45 Hairy cell leukemia (HCL) is a rare, indolent B-cell dis

46 Hairy cell leukemia (HCL) is an indolent B-cell neoplasm

47 Hairy cell leukemia (HCL) is an uncommon, indolent, chro

48 Hairy cell leukemia (HCL) is characterized by underexpre

49 Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic

50 Hairy cell leukemia (HCL) is marked by near 100% mutatio

51 One hairy cell leukemia (HCL) patient achieved a complete re

52 Hairy cell leukemia (HCL) shows unique clinicopathologic

53 iral oncogene homolog B1 (BRAF) mutations in hairy cell leukemia (HCL) subsets, demonstrating that BR

54 To compare hairy cell leukemia (HCL) with chronic lymphocytic leuke

55 produce high response rates in patients with hairy cell leukemia (HCL), a significant number of patie

56 ), 7 of 7 follicular lymphoma (FL), 13 of 17 hairy cell leukemia (HCL), and 2 of 3 mantle cell lympho

57 ch as chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL), are associated with myelosupp

58 target on B-cell malignancies, particularly hairy cell leukemia (HCL), but its soluble extracellular

59 sions (CRs) in the majority of patients with hairy cell leukemia (HCL), neither the actual relapse ra

60 These included Hodgkin's disease (HD), hairy cell leukemia (HCL), non-Hodgkin's lymphoma (NHL),

61 e (BRAF V600E) is the key driver mutation in hairy cell leukemia (HCL), suggesting opportunities for

62 However, in hairy cell leukemia (HCL), these processes are particula

63 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory s

64 ious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).

65 recently described as a molecular marker of hairy cell leukemia (HCL).

66 duces protracted remissions in patients with hairy cell leukemia (HCL).

67 nd also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL).

68 accepted as the agent of choice in treating hairy cell leukemia (HCL).

69 tibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL).

70 ates when used as first-line monotherapy for hairy cell leukemia (HCL); however, patients continue to

71 low-grade follicular lymphoma (FL; n = 44), hairy cell leukemia (HCL; n = 15), and reactive lymphoid

72 ity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies h

73 ibine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv).

74 Hairy cell leukemia is a chronic B-cell disorder that fo

75 Hairy cell leukemia is an indolent, chronic B-cell lymph

76 Hairy cell leukemia is an uncommon hematologic malignanc

77 Although hairy cell leukemia is uniquely sensitive to interferon-

78 , an immunotoxin with impressive activity in hairy cell leukemia, is in phase II trials in CLL as wel

79 N-alpha2b were approved for the treatment of hairy cell leukemia just 11 years ago.

80 al blood samples obtained from patients with hairy cell leukemia, marginal zone lymphoma, and chronic

81 lymphoma, CLL, acute lymphoblastic leukemia, hairy cell leukemia, non-Hodgkin lymphoma (including rit

82 splenomegaly, constitutional symptoms due to hairy cell leukemia, or recurrent serious infections.

83 Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerg

84 Treatment of hairy cell leukemia should be considered for symptomatic

85 Immunophenotypic features in classic hairy cell leukemia show that the leukemic cells express

86 entostatin is a highly effective regimen for hairy cell leukemia that produces durable complete respo

87 BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment wi

88 Hairy-cell leukemia that is resistant to treatment with

89 induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with

90 utcome of young patients with a diagnosis of hairy cell leukemia treated with cladribine.

91 Hairy cell leukemia variant (HCLv) presents with high di

92 isms driving variant and IGHV4-34-expressing hairy-cell leukemias, we performed whole-exome sequencin

93 A total of 358 patients with hairy cell leukemia were treated with cladribine at 0.08

94 d many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can

95 d many complete remissions in drug-resistant Hairy cell leukemia, where many treatment cycles can be

96 notoxin treatment and report that samples of hairy cell leukemia with high levels of Bim protein resp

97 ts profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and